Trial reportBlood2010
High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up.
Trial report in Blood, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02828592 (A Study of T-Cell Replete, HLA-Mismatched Haploidentical Bone Marrow Transplantation With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Lacking HLA-Matched Related Donor), which is not on this map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Study of T-Cell Replete, HLA-Mismatched Haploidentical Bone Marrow Transplantation With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Lacking HLA-Matched Related Donor
Who cites it
60 citing papers in PubMed, 121 citations in OpenAlex.
- Low-dose cyclophosphamide combined with standard immunosuppressive therapy improves early response rates in severe aplastic anemia.Frontiers in immunology · 2026Trial
- Trial
- High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases.Medicine · 2011Trial
- Posttransplant cyclophosphamide in HLA-matched peripheral blood transplantation: what's next?Blood · 2026Review
- Effective treatment of refractory aplastic anemia with romiplostim after failure of multiple thrombopoietin receptor agonists: a single-center retrospective study.Annals of medicine · 2025Article
- Umbilical cord blood infusion in the treatment of aplastic anemia: A single center prospective study.Scientific reports · 2025Article
- Towards graft-Haematologica · 2025Review
- High-dose Cyclophosphamide Without Stem Cell Rescue in Autoimmune Diseases: A Systematic Review.European journal of rheumatology · 2024Review
- Incidence of drug-related adverse events related to the use of high-alert drugs: A systematic review of randomized controlled trials.Exploratory research in clinical and social pharmacy · 2024Review
- Comparison of hematopoietic stem cell transplantation and repeated intensified immunosuppressive therapy as second-line treatment for relapsed/refractory severe aplastic anemia.Frontiers in immunology · 2024Article
- The development of post-transplant cyclophosphamide: Half a century of translational team science.Blood reviews · 2023Review
- Article
- A multicentre trial of intensive immunosuppressive therapy combined with umbilical cord blood for the treatment of severe aplastic anaemia.Annals of hematology · 2022Article
- A New Immunosuppressive Therapy for Very Severe Aplastic Anemia in Children with Autoantibodies.Current medical science · 2022Article
- [How I treat refractory sever aplastic anemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
- Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide.Blood advances · 2020Article
- Cord blood infusion-accelerated hematopoietic recovery after combined immunosuppressive therapy with fludarabine and rabbit ATG in severe aplastic anemia.International journal of hematology · 2020Article
- Haploidentical Donor Bone Marrow Transplantation for Severe Aplastic Anemia.Hematology/oncology clinics of North America · 2018Review
- Effects and Predictive Factors of Immunosuppressive Therapy Combined with Umbilical Cord Blood Infusion in Patients with Severe Aplastic Anemia.Yonsei medical journal · 2018Article
- Diagnosis and Treatment of Aplastic Anemia.Current treatment options in oncology · 2017Review
Corrections and comments
- Commented on by
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Severe aplastic anemia (SAA) is a life-threatening bone marrow failure disorder that can be treated with bone marrow transplantation, immunosuppressive therapy, and high-dose cyclophosphamide. Here, we report long-term follow-up on 67 SAA patients (44 treatment-naive and 23 refractory) treated with high-dose cyclophosphamide. At 10 years, the overall actuarial survival was 88%, the response rate was 71% with the majority being complete, and the actuarial event-free survival was 58% in 44 treatment-naive SAA patients. Patients with refractory SAA fared less well after high-dose cyclophosphamide therapy; at 10 years, overall actuarial survival, response, and actuarial event-free survival rates were 62%, 48%, and 27%, respectively. High-dose cyclophosphamide is highly effective therapy for severe aplastic anemia. Large randomized controlled trials will be necessary to establish how results of high-dose cyclophosphamide compare with either bone marrow transplantation or standard immunosuppressive regimens, such as antithymocyte globulin and cyclosporine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.